Gilead Sciences, Inc. $GILD Shares Bought by KCM Investment Advisors LLC

KCM Investment Advisors LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 15.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,060 shares of the biopharmaceutical company’s stock after purchasing an additional 1,460 shares during the quarter. KCM Investment Advisors LLC’s holdings in Gilead Sciences were worth $1,226,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC lifted its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $27,000. Putney Financial Group LLC grew its holdings in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares during the period. Finally, Colonial Trust Advisors grew its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider owned 110,193 shares of the company’s stock, valued at $13,011,589.44. This represents a 2.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 71,500 shares of company stock worth $8,336,040. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

GILD has been the subject of several research reports. Wells Fargo & Company lifted their price objective on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Citigroup raised their price target on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday, October 8th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Finally, Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $127.82.

Gilead Sciences Stock Down 3.7%

GILD opened at $118.84 on Friday. The firm has a market cap of $147.46 billion, a P/E ratio of 23.67, a PEG ratio of 0.81 and a beta of 0.32. The business’s fifty day simple moving average is $116.49 and its 200 day simple moving average is $112.22. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the previous year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.